Wang et al. (2021) reported that IRAK4 was found to be significantly overexpressed in glioma compared to normal brain tissue and that high IRAK4 expression correlated with advanced WHO grade, IDH wildtype, and 1p19q non-co-deletions, establishing a link between IRAK4 overexpression and decreased survival rates in glioma patients, suggesting it may be a potential oncogene regulating cell signaling pathways in glioma [32]. Here, IRAK4 is linked to central nervous system cancer.